liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Quality of life and patient-reported outcomes in endometrial cancer clinical trials: a call for action!
Medical Oncology Department, Clinical Research Department, Centre Francois Baclesse, CHU Cote de Nacre, Inserm "cancer&preventions", University of Basse Normandie, Caen, France.
Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, University of British Columbia, Vancouver, British Columbia, Canada.
Department of Clinical Oncology, University Medical Center, Leiden, the Netherlands.
Linköping University, Department of Clinical and Experimental Medicine, Division of Clinical Sciences. Linköping University, Faculty of Health Sciences.
Show others and affiliations
2014 (English)In: International Journal of Gynecological Cancer, ISSN 1048-891X, E-ISSN 1525-1438, Vol. 24, no 9, 1693-1699 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: There is increasing recognition that quality of life (QoL) and patient-reported outcomes (PROs) are of fundamental importance and particularly relevant given the relatively high likelihood of long-term survival in most women with endometrial cancer (EC). However, there has been relatively little research focused on this topic. Our objective was to analyze our current knowledge and identify research questions to be included in the design of next clinical trials.

METHODS: Analyze and critically assess reported clinical trials in EC that have included QoL and PROs as primary or secondary end points.

RESULTS: Surgery has a significant impact on physical and functional domains of QoL particularly in the first 6 months after diagnosis. Minimally invasive surgery is associated with less acute morbidity than open procedures and this persists over time. Lymphadenectomy is associated with increased incidence of lymphedema, important late effect. Adjuvant external irradiation may cause gastrointestinal and genitourinary symptoms that impact on physical functioning and which can persist over time. In contrast, vaginal brachytherapy has less toxicity and fewer late effects than external irradiation. The impact of treatment on sexuality has been poorly evaluated in EC survivors. There are few published data on QoL and PROs in patients treated with chemotherapy and the long-term impact has not been addressed. There is no evidence that palliative chemotherapy reduces symptoms and improves QoL. There are very few longitudinal studies on survivorship that is an important concern in EC survivors.

CONCLUSIONS: Although there have been some studies addressing QoL and PROs in EC, we have identified deficiencies and gaps in our knowledge. Careful consideration of QoL and PROs end points and how to include them in clinical trials will result in a better appreciation of how treatments can impact on patients QoL and lead to conduct interventions to reduce late effects.

Place, publisher, year, edition, pages
2014. Vol. 24, no 9, 1693-1699 p.
National Category
URN: urn:nbn:se:liu:diva-116543DOI: 10.1097/IGC.0000000000000299ISI: 000344611800028PubMedID: 25340294OAI: diva2:798874
Available from: 2015-03-27 Created: 2015-03-27 Last updated: 2015-08-14

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Åvall Lundqvist, Elisabeth
By organisation
Division of Clinical SciencesFaculty of Health Sciences
In the same journal
International Journal of Gynecological Cancer

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 72 hits
ReferencesLink to record
Permanent link

Direct link